糖基工程化中国仓鼠卵巢细胞：一段简短的历史。

Department of Life Sciences, Imperial College London, London SW7 2AZ, U.K.

Department of Chemical Engineering, Imperial College London, London SW7 2AZ, U.K.

Biochem Soc Trans. 2021 Apr 30;49(2):915-931. doi: 10.1042/BST20200840.

Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.

生物治疗性糖蛋白彻底改变了制药领域，新的发现和不断的改进是该行业快速发展的基础。N-糖基化是生物治疗性糖蛋白的一个关键质量属性，影响这些药物的疗效、半衰期和免疫原性。本综述将重点介绍中国仓鼠卵巢（CHO）细胞中 N-糖基化修饰的进展和未来方向，CHO 细胞是重组生物治疗生产的主力军，特别强调使用细胞系和蛋白质骨架工程等策略对抗体产品进行修饰。